Palazestrant not checked

Olema Oncology, Inc. · OP-1250

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
5 active
6 in total · 3 in the EU

What this is

How it works
How it works isn't classified yet
How it’s given
“Participants will be treated with palazestrant once daily on a 4 week (28 day) cycle. Doses evaluated in the dose-selection part will be 120 mg once daily and 90 mg once daily.”In the company’s words, NCT06016738 on ClinicalTrials.gov
Tested for
Breast Cancer (4 trials), Metastatic Breast Cancer (4 trials), ER Positive Breast Cancer (2 trials), HER2 Negative Breast Carcinoma (2 trials), Locally Advanced Breast Cancer (2 trials), Advanced Breast Cancer, Advanced or Metastatic ER+ HER2- Breast Cancer (mBC), Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) and 5 more
Main trialPhase 3
“This phase 3 clinical trial compares the safety and efficacy of palazestrant (OP-1250) to the standard-of-care options of fulvestrant or an aromatase inhibitor in women and men with breast cancer whose disease has advanced on one endocrine therapy in combination with a CDK4/6 inhibitor.”In the company’s words, NCT06016738 on ClinicalTrials.gov
Other names
OP-1250

Other drugs for Breast Cancer

All 397 drugs for Breast Cancer

Coming up3

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials6

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 31 Oct 2026 OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
Phase 3Recruiting Dec 2028 Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Phase 1Active, not recruiting Mar 2026 A Phase 1 Study of Oral OP-1250 in Combination With Palbociclib in HR+/HER2- Breast Cancer Patients
Phase 1Recruiting 30 May 2027 Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors
Phase 1Active, not recruiting 31 Dec 2027 Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
Phase 1/2Completed 30 Jul 2024 A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Palazestrant

Following is part of Solo: you see every change to Palazestrant the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in